Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affinergy Inc.

This article was originally published in Start Up

Executive Summary

Affinergy has--patented and in the freezer--peptide binders that stick specifically to the common materials of which medical implants are made, for example, collagen, titanium and stainless steel. These are the starting point for the company's device coating platform. The other part of the biocoating, which attaches to the device-binding peptide by a linker, is a peptide that binds to a specific protein or cell type of interest to a partner.

You may also be interested in...



Biocoatings: Not Just the Icing on the Cake

The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.

ASA Finds 'Irresponsible' Weight Loss Ad Difficult To Stomach

Vision Healthcare’s Sensilab pulled Facebook advertisements for its weight loss supplements after UK regulator the Advertising Standards Authority launched an investigation into whether the marketing, which featured slim models, was "irresponsible." 

Obituary: Wolfgang Ollig, Stada CFO

The death has been announced of Stada’s chief financial officer, Wolfgang Ollig.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel